

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): February 28, 2019**

---

**ENANTA PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-35839**  
(Commission  
File Number)

**04-3205099**  
(IRS Employer  
Identification No.)

**500 Arsenal Street, Watertown, Massachusetts 02472**  
(Address of principal executive offices, including zip code)

**(617) 607-0800**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

- Written communications pursuant to rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17, CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

At the annual meeting of stockholders held on February 28, 2019, Enanta's stockholders voted on the following proposals, each of which is described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 18, 2019.

**Proposal No. 1: To Elect Two Class III Directors to Serve Until the 2022 Annual Meeting of Stockholders.**

The stockholders re-elected the following individuals as Class III directors of the Company:

<u>Name of Director Nominee</u>	<u>Votes For</u>	<u>Votes Withheld</u>	<u>Broker Non-Votes</u>
Stephen Buckley, Jr.	14,546,299	111,236	1,438,218
Lesley Russell	14,551,689	105,846	1,438,218

**Proposal No. 2: To Approve the 2019 Equity Incentive Plan.**

The stockholders approved the 2019 Equity Incentive Plan.

<u>Votes For</u>	<u>Votes Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
8,719,605	5,927,973	9,957	1,438,218

**Proposal No. 3: To Approve, on an Advisory Basis, the Frequency of Holding an Advisory Vote on the Compensation Paid to the Company's Named Executive Officers.**

The stockholders approved the frequency of holding an advisory vote on compensation paid to the Company's named executive officers.

<u>Each Year</u>	<u>2 Years</u>	<u>3 Years</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
14,157,448	8,587	477,415	14,084	1,438,219

**Proposal No. 4: To Approve, on an Advisory Basis, the Compensation Paid to the Company's Named Executive Officers.**

The stockholders approved the advisory vote on executive compensation, or a "say-on-pay" vote.

<u>Votes For</u>	<u>Votes Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
14,439,535	195,192	22,807	1,438,219

**Proposal No. 5: To Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta's Independent Registered Public Accounting Firm for the 2019 Fiscal Year.**

The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending September 30, 2019.

<u>Votes For</u>	<u>Votes Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
15,925,976	153,158	16,619	0

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 6, 2019

**ENANTA PHARMACEUTICALS, INC.**

By:/s/ Jay R. Luly, Ph.D.

---

Jay R. Luly, Ph.D.  
Chief Executive Officer